late
decemb
group
patient
pneumonia
unknown
caus
confirm
infect
novel
coronaviru
wuhan
china
infect
ten
thousand
peopl
china
spread
rapidli
around
globe
world
health
organ
declar
coronaviru
diseas
public
health
emerg
intern
concern
releas
interim
guidelin
patient
manag
due
sever
spread
novel
coronaviru
pneumonia
ncp
chines
govern
medic
institut
execut
strict
strategi
control
influenc
epidem
end
februari
epidem
control
great
extent
nation
wuhan
situat
tend
stabl
high
proport
critic
ill
patient
still
treatment
intens
care
coronavirus
cov
envelop
virus
singl
positivestrand
rna
genom
kb
length
cov
mainli
caus
respiratori
tract
infect
strain
high
infect
mortal
well
heavi
damag
public
health
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
group
similar
genet
sequenc
sarsncov
latest
version
diagnosi
treatment
plan
point
main
transmiss
rout
droplet
transmiss
close
contact
transmiss
addit
risk
airborn
spread
aerosolgener
medic
procedur
specif
circumst
clinic
manifest
fever
headach
dri
cough
radiolog
evid
viral
pneumonia
sever
case
dyspnea
usual
occur
week
diseas
onset
patient
rapidli
progress
acut
respiratori
distress
syndrom
ard
septic
shock
refractori
metabol
acidosi
coagul
disord
addit
clinic
featur
asymptomat
case
obviou
except
posit
nucleic
acid
oropharyng
swab
asymptomat
case
also
risk
although
weak
transmiss
respiratori
viral
infect
caus
sever
ill
especi
elderli
person
comorbid
accord
latest
version
diagnosi
treatment
guidelin
confirm
case
infect
classifi
sever
ill
compli
one
follow
symptom
anhel
respiratori
rate
timesmin
oxygen
satur
rest
mmhg
classifi
criticallifethreaten
ill
compli
one
follow
symptom
respiratori
failur
mechan
ventil
need
shock
organ
dysfunct
syndrom
requir
intens
care
unit
admiss
progress
sever
ill
usual
rapid
clear
separ
sever
ill
critic
ill
therefor
patient
two
class
combin
critic
ill
help
health
care
worker
diagnos
treat
patient
intens
care
resourc
earli
stage
critic
ill
diagnost
evid
icu
admiss
accord
previou
experi
treatment
sar
includ
old
age
year
old
presenc
comorbid
particularli
diabet
mellitu
hepat
cardiac
diseas
elev
lactat
dehydrogenas
level
admiss
hospit
invad
respiratori
mucosa
infect
cell
induc
cytokin
storm
system
patient
may
progress
rapidli
ard
dissemin
intravascular
coagul
dic
septic
shock
eventu
multipl
organ
failur
therefor
earli
identif
time
treatment
critic
case
crucial
import
evidencebas
therapi
support
care
icu
mainstay
manag
sever
lifethreaten
ill
sever
critic
ill
treat
icu
hospit
nosocomi
infect
control
strict
volum
manag
multiorgan
function
evalu
critic
care
nutrit
assessmentappropri
nutrit
support
essenti
patient
icu
addit
attent
paid
bedbound
patient
prevent
deep
vein
thrombosi
nucleosid
analog
broadspectrum
antivir
effect
via
mechan
lethal
mutagenesi
chain
termin
inhibit
nucleotid
biosynthesi
fabiravir
ribavirin
repres
drug
nucleosid
analog
exhibit
antivir
effect
inhibit
nucleotid
biosynthesi
demonstr
combin
fabiravir
oseltamivir
treatment
sever
influenza
may
acceler
clinic
recoveri
oseltamivir
alon
addit
report
combin
ribavirin
interferon
alpha
significantli
reduc
mortal
critic
ill
patient
infect
mer
although
mortal
affect
ribavirin
also
use
treatment
sar
howev
ribavirin
might
side
effect
anemia
liver
injuri
may
improv
patient
outcom
therefor
use
ribavirin
treatment
need
elucid
clinic
studi
lopinavirritonavir
proteas
inhibitor
treatment
hiv
infect
lopinavirritonavir
show
antivir
activ
inhibit
replic
coronaviru
vitro
report
combin
lopinavirritonavir
ribavirin
could
lower
risk
ard
compar
ribavirin
alon
recent
random
clinic
trial
lopinavirritonavir
mg
twicedaili
day
treatment
cao
et
al
shown
hospit
adult
patient
sever
benefici
effect
observ
lopinavirritonavir
treatment
compar
standard
care
group
advers
effect
lopinavirritonavir
treatment
includ
anorexia
nausea
abdomin
discomfort
diarrhea
acut
gastriti
moreov
risk
hepat
injuri
pancreat
sever
cutan
erupt
well
drug
interact
due
inhibit
observ
clinic
trial
arous
concern
use
higher
prolong
dose
regimen
outcom
improv
addit
seriou
complic
acut
kidney
injuri
secondari
infect
fewer
receiv
treatment
futur
trial
sever
ill
might
help
elucid
possibl
benefit
lopinavirritonavir
treatment
remdesivir
new
nucleosid
analog
recogn
potenti
promis
antivir
drug
wide
array
rna
virus
includ
sarsmerscov
current
clinic
develop
treatment
ebola
viru
infect
remdesivir
potenti
inhibit
rnadepend
rna
polymeras
merscov
reduc
viru
replic
decreas
viru
titer
mous
lung
infect
merscov
improv
lung
tissu
damag
antivir
activ
remdesivir
ifnbeta
found
superior
combin
lopinavirritonavir
ifnbeta
merscov
random
control
trial
report
prolong
use
remdesivir
treatment
ebola
viru
diseas
evd
safe
advers
event
observ
candid
drug
approv
inform
side
effect
remdesivir
report
yet
present
two
random
control
doubleblind
clinic
trial
ongo
evalu
efficaci
safeti
remdesivir
mg
load
dose
day
follow
mg
iv
oncedaili
mainten
dose
day
hospit
patient
mildmoder
sever
respiratori
diseas
result
clinic
trial
may
open
window
effect
antivir
therapi
epidem
infecti
diseas
arbidol
small
indolederiv
molecul
approv
prophylaxi
treatment
influenza
respiratori
viral
infect
also
show
inhibitori
activ
virus
envelop
respons
emerg
global
preval
infecti
diseas
hepat
b
c
addit
arbidol
report
antivir
activ
pathogen
sar
effect
arbidol
deriv
arbidol
almost
five
time
higher
arbidol
reduc
reproduct
sar
cell
vitro
claim
arbidol
effect
vitro
random
multicent
control
clinic
trial
arbidol
patient
progress
china
known
angiotensinconvert
membran
protein
function
receptor
sarscov
facilit
viru
entri
cell
bind
spike
protein
viru
mediat
fusion
viral
host
membran
therefor
may
import
block
bind
protein
treat
viral
infect
sarscov
chloroquin
known
sinc
sulfat
phosphat
salt
commerci
wide
use
antimalari
autoimmun
diseas
drug
chloroquin
also
show
broadspectrum
antivir
effect
found
potent
inhibitor
sarscov
infect
due
inhibitori
effect
demonstr
enter
epitheli
cell
oral
mucosa
via
essenti
receptor
chloroquin
function
entri
postentri
stage
infect
besid
antivir
activ
chloroquin
immunemodul
activ
may
synergist
enhanc
antivir
effect
vivo
recent
wang
et
al
demonstr
chloroquin
highli
effect
control
infect
vitro
suggest
assess
human
patient
suffer
addit
result
patient
indic
chloroquin
phosphat
superior
control
treatment
inhibit
exacerb
pneumonia
improv
lung
imag
promot
viru
neg
convers
shorten
diseas
cours
howev
attent
paid
potenti
detriment
effect
chloroquin
observ
previou
attempt
treat
viral
diseas
present
clinic
trial
evalu
efficaci
safeti
chloroquin
treatment
ongo
use
chloroquin
treatment
refer
recent
announc
addit
hydroxychloroquin
deriv
antimalari
drug
hydroxychloroquin
immunosuppress
drug
matur
clinic
applic
treatment
rheumat
immun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
found
potent
chloroquin
inhibit
vitro
hydroxychloroquin
sulfat
mg
given
twice
daili
day
follow
mg
twice
daili
anoth
day
recommend
treatment
present
clinic
evalu
hydroxychloroquin
treatment
progress
might
shortli
provid
preliminari
result
effect
hydroxychloroquin
patient
pneumonia
especi
sever
condit
may
encount
coinfect
crossinfect
bacteri
pathogen
instanc
staphylococcu
aureu
medic
treatment
hospit
consid
high
incid
bacteri
infect
critic
ill
patient
essenti
test
kinet
procalcitonin
pct
creaction
protein
crp
patient
time
diagnosi
intervent
bacteri
infect
accord
recent
atsidsa
clinic
practic
guidelin
besid
antivir
treatment
patient
viralinfect
pneumonia
clinician
empir
give
antibacteri
therapi
patient
initi
sever
diseas
extens
pneumonia
respiratori
failur
hypotens
fever
deterior
initi
improv
fail
improv
day
antivir
treatment
thu
antibiot
treatment
recommend
treatment
patient
base
evid
bacteri
infect
blind
inappropri
use
antibiot
especi
broadspectrum
antibiot
avoid
use
corticosteroid
treatment
ard
controversi
observ
data
sar
suggest
immunomodul
regimen
highdos
methylprednisolon
might
help
modul
inflammatori
respons
lung
damag
hand
studi
show
use
steroid
associ
increas
risk
bacteri
infect
increas
mortal
even
antivir
resist
influenzaassoci
pneumonia
ard
moreov
multipl
studi
report
corticosteroid
treatment
associ
delay
viral
shed
hospit
patient
without
signific
chang
mortal
corticosteroid
therapi
patient
mer
shown
associ
differ
mortal
associ
delay
mer
coronaviru
rna
clearanc
earli
use
parenter
glucocorticoid
therapi
fever
reduct
pneumonia
prevent
shown
increas
risk
critic
diseas
death
infect
current
limit
clinic
research
support
use
corticosteroid
treatment
ard
patient
improv
outcom
patient
recommend
corticosteroid
use
treatment
viral
pneumonia
ard
convinc
proof
therapeut
benefit
corticosteroid
treatment
still
need
demonstr
clinic
research
thymosin
thymic
peptid
hormon
signific
benefit
restor
homeostasi
host
immun
system
chemic
synthes
use
diseas
impair
immun
system
report
low
lymphocyt
count
associ
poor
prognosi
septic
patient
use
thymosin
therapi
combin
convent
medic
therapi
effect
improv
clinic
outcom
reduc
mortal
sever
sepsi
addit
thymosin
enhanc
immun
respons
sar
patient
help
limit
spread
sar
therefor
although
clinic
evid
show
benefici
effect
thymosin
recommend
use
patient
enhanc
cellular
immun
resist
viral
infect
cyclosporin
wide
use
transplant
autoimmun
disord
due
immunosuppress
effect
cyclophilin
key
member
immunophilin
cellular
receptor
cyclosporin
inhibit
cyclophilin
cyclosporin
could
block
replic
coronaviru
includ
sarscov
therefor
nonimmunosuppress
deriv
cyclosporin
might
serv
broadrang
cov
inhibitor
applic
emerg
viru
like
still
need
confirm
clinic
studi
futur
two
type
interferon
ifn
type
ifn
type
ii
ifn
demonstr
type
ifn
inhibit
replic
sar
merscov
kuri
et
al
report
ifn
transcript
block
tissu
cell
infect
sarscov
cell
infect
sarscov
abl
partial
restor
innat
immun
respons
sarscov
prime
small
amount
ifn
moreov
patient
sever
merscov
infect
combin
ribavirin
shown
improv
surviv
recent
combin
remdesivir
ifnbeta
shown
signific
antivir
activ
intraven
gammaglobulin
consid
safest
immunomodul
drug
avail
treatment
sever
infect
sepsi
high
titer
neutral
antibodi
broadspectrum
viru
bacteria
pathogen
modul
host
immun
respons
sever
way
howev
largescal
multicent
random
placebocontrol
trial
show
improv
surviv
intraven
gammaglobulin
sever
sepsi
moreov
cochran
review
show
intraven
gammaglobulin
reduc
mortal
septic
patient
therefor
convinc
argument
recommend
intraven
gammaglobulin
treatment
one
import
mechan
underli
deterior
cytokin
storm
character
elev
level
ifn
cytokin
lead
ard
even
multipl
organ
failur
tocilizumab
recombin
human
monoclon
antibodi
bind
receptor
inhibit
signal
transduct
tocilizumab
use
treatment
rheumatoid
arthriti
ra
moreov
tocilizumab
report
effect
cytokin
releas
syndrom
induc
cart
cell
infus
b
cell
acut
lymphoblast
leukemia
diagnosi
treatment
guidelin
ncp
trial
version
tocilizumab
recommend
immunotherapi
patient
extens
lung
lesion
sever
case
show
increas
level
laboratori
test
efficaci
tocilizumab
patient
still
need
investig
chines
tradit
medicin
use
prevent
treat
sar
pandem
influenza
tradit
chines
medicin
china
issu
chines
tradit
medicin
prevent
program
includ
sever
chines
herbal
medicin
formula
prevent
infect
adult
children
shufengjiedu
capsul
lianhuaqingwen
capsul
also
play
role
prevent
treatment
new
respiratori
infecti
diseas
influenza
studi
confirm
yupingfeng
powder
antivir
antiinflammatori
immunoregulatori
effect
multicent
largescal
random
trial
found
yinqiao
powder
plu
anoth
heatclear
formula
could
reduc
time
fever
resolut
patient
influenza
viru
infect
suggest
highrisk
popul
expos
patient
includ
medic
staff
famili
member
peopl
close
contact
patient
well
resid
live
outbreak
area
might
benefit
take
chines
tradit
medicin
formula
prevent
howev
efficaci
safeti
chines
tradit
medicin
formula
need
confirm
clinic
trial
convalesc
plasma
deriv
patient
antibodi
effect
reduc
mortal
rate
critic
ill
patient
infecti
diseas
convalesc
plasma
found
immunotherapeut
potenti
treatment
mer
sar
ebola
viru
diseas
explan
efficaci
convalesc
plasma
therapi
antibodi
convalesc
plasma
might
suppress
viremia
via
free
viral
clearanc
blockad
new
infect
well
acceler
infect
cell
clearanc
addit
use
hightit
mer
serum
camel
could
significantli
improv
histolog
lung
damag
increas
clearanc
merscov
mice
moreov
use
convalesc
plasma
serum
also
suggest
blood
regul
network
vaccin
antivir
drug
unavail
emerg
viru
evid
show
convalesc
plasma
therapi
associ
occurr
sever
advers
event
convalesc
plasma
avail
use
treatment
critic
ill
patient
evalu
valenc
antibodi
worthwhil
test
efficaci
safeti
convalesc
plasma
transfus
patient
oxygen
therapi
highflow
nasal
cannula
noninvas
ventil
may
reduc
need
endotrach
intub
decreas
ventilatorassoci
complic
mortal
howev
sever
studi
report
failur
noninvas
ventil
invas
ventil
ultim
requir
treatment
sever
influenza
canada
noninvas
ventil
may
effect
safe
patient
wherea
might
increas
viru
transmiss
health
care
worker
risk
infect
aerosol
gener
therefor
treatment
noninvas
ventil
may
use
select
patient
earli
stage
milder
acut
hypoxem
respiratori
failur
critic
ill
patient
effect
transit
oxygen
therapi
respiratori
statu
oxygen
index
need
close
monitor
switch
mechan
ventil
necessari
highflow
nasal
cannula
emerg
altern
noninvas
ventil
prevent
intub
reduc
mortal
patient
acut
hypoxem
respiratori
failur
highflow
nasal
cannula
report
significantli
reduc
mortal
communityacquir
pneumonia
compar
standard
oxygen
noninvas
ventil
hui
et
al
shown
breath
dispers
distanc
limit
therefor
lower
risk
air
transmiss
howev
loos
connect
cannula
nasal
obstruct
significantli
increas
dispers
distanc
wear
mask
particularli
effect
reduc
breath
dispers
distanc
highflow
nasal
ventil
prevent
nosocomi
transmiss
addit
highflow
nasal
cannula
might
increas
viru
transmiss
risk
due
aerosol
gener
therefor
staff
protect
health
care
worker
critic
mechan
ventil
patient
sever
ard
manag
lungprotect
strategi
minim
ventilatorassoci
lung
injuri
improv
surviv
approach
minim
ventilatorassoci
lung
injuri
improv
surviv
includ
ventil
low
tidal
volum
mlkg
predict
bodi
weight
target
plateau
pressur
minim
inspir
oxygen
concentr
decreas
oxygen
toxic
high
posit
endexpiratori
pressur
peep
reduc
need
high
improv
ga
exchang
lung
complianc
wherea
high
peep
may
lead
lung
overdistens
hemodynam
instabl
optim
peep
titrat
curv
oxygen
stress
index
electr
imped
tomographi
eit
ultrasound
clinic
paramet
associ
improv
surviv
rate
among
sever
ard
patient
lung
recruit
need
evalu
mechan
ventil
patient
uncorrect
hypoxemia
occur
lung
recruit
execut
patient
whose
lung
restor
aerat
ct
eit
ultrasound
bedsid
techniqu
use
evalu
lung
recruit
lung
recruit
critic
ill
patient
manag
mechan
ventil
excess
spontan
breath
due
stretch
may
lead
lung
injuri
therefor
neuromuscular
relax
may
use
control
spontan
breath
protect
lung
prone
posit
ventil
techniqu
often
improv
oxygen
ard
possibl
improv
match
uniform
ventil
gravityrel
atelectasi
prone
ventil
use
mechan
ventil
sar
patient
without
enough
data
draw
conclus
regard
efficaci
although
prone
ventil
show
improv
surviv
organ
dysfunct
overal
might
benefici
patient
sever
ard
multicent
rct
demonstr
earli
applic
prone
posit
patient
sever
ard
result
decreas
mortal
addit
use
prone
posit
patient
influenzainduc
sever
ard
shown
relat
improv
oxygen
sustain
return
supin
posit
decreas
carbon
dioxid
retent
gener
speak
prone
posit
ventil
less
h
daili
rel
safe
procedur
rare
worsen
patient
respiratori
statu
thu
recommend
treatment
sever
ard
ecmo
becom
import
lifesupport
strategi
standard
treatment
ard
patient
ecmo
consid
earli
possibl
lung
recruit
prone
posit
ventil
show
ineffect
observ
studi
report
patient
ard
induc
influenza
show
lower
hospit
mortal
transfer
ecmo
center
compar
match
nonecmosupport
patient
use
ecmo
also
show
surviv
benefit
patient
sever
mer
ecmo
tend
improv
patient
outcom
use
among
limit
organ
failur
good
premorbid
function
statu
substanti
proport
critic
ill
patient
appear
develop
cardiac
arrhythmia
shock
may
need
ecmo
support
howev
develop
septic
shock
refractori
multipl
organ
failur
ecmo
suggest
due
less
benefit
ecmo
resourceintens
highli
special
expens
form
life
support
potenti
signific
complic
hemorrhag
nosocomi
infect
therefor
use
ecmo
strictli
limit
treatment
moreov
sinc
number
critic
ill
patient
still
increas
resourc
ecmo
finit
judgment
need
decid
ecmo
may
worthwhil
may
support
ecmo
suppos
critic
ill
patient
region
extens
resourc
therapi
patient
ard
restrict
time
fluid
resuscit
associ
better
oxygen
lower
mortal
aggress
fluid
administr
may
worsen
oxygen
ventricular
dysfunct
may
result
longer
durat
mechan
ventil
even
mortal
therefor
necessari
assess
fluid
respons
evalu
ventricular
function
fluid
resuscit
conserv
fluid
administr
maintain
adequ
mean
arteri
pressur
organ
perfus
appropri
use
diuret
vasopressor
import
accord
latest
epidemiolog
report
incid
critic
ill
patient
develop
multipl
organ
dysfunct
syndrom
may
combin
organ
injuri
includ
liver
injuri
cardiac
dysfunct
coagulopathi
may
need
routin
function
support
critic
ill
patient
icu
moreov
critic
ill
patient
admit
icu
neg
nitrogen
balanc
malnutrit
consid
contribut
factor
emerg
viral
infecti
diseas
therefor
appropri
nutrit
strategi
pivot
treatment
critic
ill
necessari
specif
antivir
drug
vaccin
present
therefor
import
enhanc
host
immun
respons
infect
drug
option
base
experi
treat
sar
mer
previou
influenza
virus
efficaci
exist
drug
well
adjunct
pharmacolog
intervent
treatment
critic
ill
patient
warrant
verif
clinic
research
complet
stop
epidem
spread
vaccin
urgent
need
besid
enhanc
host
immun
respons
viral
infect
appropri
respiratori
support
strategi
monitor
support
multipl
organ
function
modul
immun
statu
inflammatori
respons
individu
well
prophylaxi
treatment
complic
import
guarante
recoveri
critic
ill
patient
better
understand
novel
viru
research
need
done
get
optim
strategi
treatment
